White Paper: Meeting the Analytic Challenges of Value-Based Agreements in Life Sciences

Uncertainty about the real-world effectiveness and value of a new product or a new indication can hinder market access, especially for products with no real-world data available or relatively small clinical trials  Value-based agreements (VBA) can help reassure payers in these circumstances and ensure that manufacturers earn an appropriate return in the event the product works as they expect it to.

View the White Paper >>

EntityRisk Webcast Series Episode 1: 2023 – How to determine commercial value in a downturn

How can you predict how payers around the world will value new therapies when caution remains the dominant theme of 2023? Darius Lakdawalla and EntityRisk CEO Neal Masia answer that question in this recent webcast. They also discuss the news from JPM 2023 and review formulas for success in a prolonged downturn.

View the Webcast >>